Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief ...

Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

University of Missouri researchers and collaborators have developed a new chemical tool that could help lower the cost of ...

Ligand Pharmaceuticals has made its second major acquisition in 2024, agreeing a $100 million deal to buy Austria’s Apeiron Biologics and a royalty stream for brain cancer drug Qarziba.

Investors took in Amazon earnings, with the all-important jobs report on deck. There are a number of stocks moving in after-hours trading.  E.l.f. Beauty (ELF) shares fell sharply after ...

These modules allow the ProteinReDiff framework to capture intricate protein–ligand interactions, improve the fidelity of binding affinity predictions and enable more precise redesigns of ligand ...

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and ...

Researchers now offer a simplified method they call ProteinReDiff that uses artificial intelligence to speed the redesign of ligand-binding proteins. In biology, the binding of cellular proteins ...

Researchers have developed a new chemical tool that could help lower the cost of prescription medications. The tool, called AshPhos, is a ligand, or molecule, that makes it easier to create special ...